Supreme Court of the United States · Official docket →
PharMerica Corporation v. United States, ex rel. Marc Silver
Paid petition · United States Court of Appeals for the Third Circuit, No. 16-4418 · judgment September 4, 2018
Before the decision, roughly the 4.1% base rate. The model weighted this up for a Third Circuit decision below, a circuit split argued in the petition, and a business petitioner.
Question presented
The Public Disclosure Bar (the “Bar”) of the False Claims Act (“FCA”), 31 U.S.C. § 3730(e)(4), provides that courts must dismiss an FCA case brought as a qui tam action by a relator who is not an original source of the information in his complaint “if substantially the same allegations or transactions as alleged in the action were publicly disclosed” in certain enumerated sources.1 The Bar functions as a gatekeeping device to prevent parasitic lawsuits based on previously disclosed information, while allowing true insiders to advance new claims. The Circuits have been unable to devise a uniform standard for ascertaining when the Bar applies, and in doing so have deviated from the plain language of the Bar, resulting in conflict and confusion among the Circuits. The questions presented are: 1. Whether a relator’s admission that he, in fact, derived his complaint from public disclosures triggers the Bar, requiring an analysis of whether such a relator is an original source of the information in his complaint, as every other Circuit to consider the issue has held 1 Prior to its amendment in 2010, the Bar provided that “[n]o court shall have jurisdiction over an action under this section based upon the public disclosure of allegations or transactions” in certain enumerated sources “unless the person bringing the action is an original source of the information.” 31 U.S.C. § 3730(e)(4) (2006).
Counsel of record
For petitioner
Michael Robert Manthei
Holland & Knight LLP
For respondent
Sherrie R. Savett
Berger & Montague
Case
Conference history
Distributed for 2 conferences
Proceedings
- Oct 07 2019Motion for leave to file amici brief filed by Pharmaceutical Research and Manufacturers of America, et al. GRANTED.
- Oct 07 2019Petition DENIED.
- Jun 19 2019DISTRIBUTED for Conference of 10/1/2019.
- Jun 17 2019Reply of petitioner PharMerica Corporation filed. (Distributed)
- Jun 03 2019Brief of respondent United States, ex rel. Marc Silver in opposition filed.
- May 03 2019Motion to extend the time to file a response is granted and the time is extended to and including June 3, 2019.
- May 01 2019Motion to extend the time to file a response from May 3, 2019 to June 3, 2019, submitted to The Clerk.
- Apr 03 2019Response Requested. (Due May 3, 2019)
- Mar 27 2019DISTRIBUTED for Conference of 4/12/2019.
- Mar 11 2019Motion for leave to file amici brief filed by Pharmaceutical Research and Manufacturers of America, et al.
- Mar 04 2019Blanket Consent filed by Petitioner, PharMerica Corporation
- Feb 06 2019Petition for a writ of certiorari filed. (Response due March 11, 2019)